Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
Shilpa Singh, Catherine E. Gleason, Min Fang, Yasmin N. Laimon, Vishal Khivansara, Shanhai Xie, Yavuz T. Durmaz, Aniruddha Sarkar, Kenneth Ngo, Varunika Savla, Yixiang Li, Muhannad Abu-Remaileh, Xinyue Li, Bishma Tuladhar, Ranya Odeh, , Matthew G. Oser
This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.
bioRxiv · Aug 1, 2024 · PreprintCancer Biology